Drug cocktail aims to shrink stomach tumors before surgery in small trial

NCT ID NCT07151209

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy (SOX) in 20 people with a specific type of advanced stomach or gastroesophageal junction cancer (MSI-H/dMMR). The goal is to see if this treatment can completely eliminate the tumor before surgery, potentially improving outcomes. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iparomlimab, tuvonralimab, lenvatinib, and SOX chemotherapy (oxaliplatin and S-1)
What this could lead to
If successful, this combination could shrink advanced gastric tumors enough to allow surgical removal, potentially improving long-term survival.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The drug combination also carries risks of serious side effects like immune reactions and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.